Biopharma bites: Tolerability sinks Vertex-Moderna's CF candidate, Takeda's immune win, and more from Amgen, Latus

BioPharma DiveCytospire hauls in $83M for a new type of T cell engager

Samsung BiologicsSamsung Biologics Labor Talks Break Down, Gap Remains - thelec.net

Siemens HealthineersCDC HoSt-TT certification for Siemens Healthineers total testosterone test expands patient access to gold standard equivalent results - News-Medical

Samsung BiologicsSamsung Biologics union continues first general strike, demands higher wages and performance-based pay - Korea JoongAng Daily

FierceBiotechPrivate Swiss biotechs hit record funding amid slowdown in public financing

Samsung BiologicsSamsung Biologics' strike enters 5th day - Yonhap News Agency

eLifeAre kinocilia motile?

eLifeHuman adherent cortical organoids in a multi-well format

Endpoints NewsVertex drops mRNA cystic fibrosis program over 'tolerability' issues

Bio-RadBio-Rad Navigates Academic Headwinds and Geopolitical Shifts in Q1 2026 Financial Results - Lab Manager

FierceBiotechVertex drops Moderna-partnered inhaled cystic fibrosis candidate after unresolved tolerability issues